Vertex Pharmaceuticals

YTD

ALL

Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.

CEO

Reshma Kewalramani

CEOReshma Kewalramani

Employees

6,100

Employees6,100

Headquarters

Boston, Massachusetts

HeadquartersBoston, Massachusetts

Founded

1989

Founded1989

Employees

6,100

Employees6,100

VRTX Key Statistics

Market cap

96.34B

Market cap96.34B

Price-Earnings ratio

27.57

Price-Earnings ratio27.57

Dividend yield

—

Dividend yield—

Average volume

3.05M

Average volume3.05M

High today

$388.85

High today$388.85

Low today

$374.45

Low today$374.45

Open price

$385.00

Open price$385.00

Volume

4.00M

Volume4.00M

52 Week high

$519.88

52 Week high$519.88

52 Week low

$372.35

52 Week low$372.35

VRTX News

Seeking Alpha 3d

Vertex plunges as trial setback overshadows Q2 beat

Vertex Pharmaceuticals (NASDAQ:VRTX) shares plunged on Tuesday despite the company posting second quarter revenue and adjusted profit above expectations. The s...

Seeking Alpha 3d

Vertex reiterates $11.85B–$12B 2025 revenue guidance while boosting JOURNAVX commercial investment

Earnings Call Insights Vertex reiterates $11.85B–$12B 2025 revenue guidance while boosting JOURNAVX commercial investment Aug. 04, 2025 8:14 PM ET Vertex Pharma...

Seeking Alpha 3d

Vertex Pharmaceuticals Non-GAAP EPS of $4.52 beats by $0.27, revenue of $2.96B beats by $50M

Earnings News Vertex Pharmaceuticals Non-GAAP EPS of $4.52 beats by $0.27, revenue of $2.96B beats by $50M Aug. 04, 2025 4:02 PM ET Vertex Pharmaceuticals Incor...

Analyst ratings

57%

of 35 ratings

Buy

57.1%

Hold

40%

Sell

2.9%

People also own

Based on the portfolios of people who own VRTX. This list is generated using Robinhood data, and it’s not a recommendation.

Sprouts Farmers Market

Gilead Sciences